AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +72

Cantor Fitzgerald Issues Positive Forecast for AbbVie (NYSE:ABBV) Stock ...

📈 Cantor Fitzgerald raised its price target for AbbVie from $265 to $285 while maintaining an overweight rating.

📊 The company reported Q2 earnings of $3.65 per share, beating the consensus estimate of $3.61 by $0.04.

💰 Revenue for the quarter reached $16.99 billion, exceeding analyst estimates of $16.80 billion.

📈 Year-over-year revenue growth was 10.2%, driven by strong performance across therapeutic areas.

🎯 AbbVie provided Q3 2026 earnings guidance ranging from $3.84 to $3.88 per share.

💵 A quarterly dividend of $1.73 will be paid on August 14th with an ex-dividend date of July 15th.

📉 The stock carries a negative return on equity of -466.39% for the reported quarter.

🏦 Institutional ownership stands at 70.23%, with several hedge funds increasing their holdings in Q2.

📊 Analyst consensus rating is 'Moderate Buy' with an average price target of $271.48.

🔬 AbbVie focuses on complex chronic conditions across immunology, oncology, neuroscience, and other areas.

Bullish Signals
  • Cantor Fitzgerald increased its price target to $285, signaling strong confidence in the company's near-term prospects.
  • AbbVie beat earnings expectations with $3.65 EPS compared to the consensus of $3.61.
  • Revenue of $16.99 billion exceeded analyst estimates of $16.80 billion, demonstrating solid top-line execution.
  • The company achieved a 10.2% year-over-year revenue increase, indicating sustained growth momentum.
  • Multiple major banks including JPMorgan Chase and DZ Bank have issued upgrades or maintained overweight ratings.
  • The board declared a $1.73 quarterly dividend, providing a 2.8% annualized yield to shareholders.
  • Several hedge funds, including ACT Advisors and Willner & Heller, increased their stakes during the second quarter.
Risk Factors
  • AbbVie reported a negative return on equity of -466.39%, indicating significant leverage or accounting adjustments affecting equity metrics.
  • The dividend payout ratio is 195.48%, which exceeds 100% and suggests the company is paying out more than its current quarterly earnings.
Full Analysis
Cantor Fitzgerald has raised its price target for AbbVie (NYSE: ABBV) from $265 to $285, maintaining an overweight rating. This follows a mixed landscape of recent analyst actions, including JPMorgan Chase increasing its target to $280 and DZ Bank upgrading the stock to a strong buy, while Wall Street Zen downgraded its rating to 'buy' and Citigroup kept a neutral stance. The company reported strong financial results for the quarter ended July 31, with earnings per share of $3.65 beating the consensus estimate of $3.61. Revenue reached $16.99 billion, surpassing analyst expectations of $16.80 billion and representing a 10.2% year-over-year increase. The business achieved a net margin of 9.80%, though it recorded a negative return on equity of 466.39%. AbbVie has set its Q3 2026 earnings guidance between $3.84 and $3.88 per share, with analysts averaging an expectation of $14.12 EPS for the current fiscal year. The company also declared a quarterly dividend of $1.73 payable on August 14th to shareholders of record as of July 15th, resulting in an annualized yield of 2.8% and a payout ratio of 195.48%. Institutional ownership remains high at 70.23%, with several hedge funds increasing their stakes during the second quarter.